Global eligibility and cost effectiveness of icosapent ethyl in primary and secondary cardiovascular prevention

Overview of attention for article published in Frontiers in Cardiovascular Medicine, August 2023

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (62nd percentile)
High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

twitter: 4 X users

Readers on

mendeley: 7 Mendeley

Summary X

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 3,255 followers.

Frontiers | Global eligibility and cost effectiveness of icosapent ethyl in primary and secondary cardiovascular prevention https://t.co/GbM4Nm0wTh

29 Nov 2023

Reply Repost Favourite

💯 "IPE is particularly cost effective in patients with established CVD".

02 Sep 2023

Reply Repost Favourite

RT @FrontCVMedicine: New Research: Global eligibility and cost effectiveness of icosapent ethyl in primary and secondary cardiovascular pre…

01 Sep 2023

Reply Repost Favourite

New Research: Global eligibility and cost effectiveness of icosapent ethyl in primary and secondary cardiovascular prevention: Icosapent ethyl (IPE) is a purified eicosapentaenoic acid–only omega-3 fatty acid that significantly reduced… #cardiovascular htt

01 Sep 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.